Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$258M in Q4 2024 → $526M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Personalis Inc | 35.8% | Unchanged | 14,044,943 | $188M |
| Moderna Inc | 30.7% | Unchanged | 2,308,190 | $162M |
| Kymera Therapeutics Inc | 16.8% | Unchanged | 772,165 | $88.5M |
| Aktis Oncology Inc | 5.8% | Unchanged | 952,844 | $30.7M |
| Eikon Therapeutics Inc | 4.1% | Unchanged | 1,666,666 | $21.7M |
| Entrada Therapeutics Inc | 2.4% | New | 1,739,768 | $12.8M |
| Sutro Biopharma Inc | 1.7% | New | 272,351 | $9.04M |
| Alector Inc | 1.4% | Unchanged | 3,545,719 | $7.13M |
| EB Evaxion Biotech A/s | 0.7% | New | 1,214,126 | $3.76M |
| VT Viridian Therapeutics Inc | 0.3% | Unchanged | 93,414 | $1.72M |
| Xilio Therapeutics Inc | 0.2% | Unchanged | 105,982 | $1.02M |
| Tuhura Biosciences Inc | 0.0% | Unchanged | 19,445 | $45.5K |
| Neuphoria Therapeutics Inc | 0.0% | Unchanged | 10,027 | $43.8K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 07, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Entrada Therapeutics Inc | Exited | −1,739,768 | −$22M | — |
| Entrada Therapeutics Inc | New | +1,739,768 | +$12.8M | 2.4% |
| Sutro Biopharma Inc | New | +272,351 | +$9.04M | 1.7% |
| Sutro Biopharma Inc | Exited | −272,351 | −$6.78M | — |
| EB Evaxion Biotech A/s | Exited | −1,214,126 | −$4.52M | — |
| EB Evaxion Biotech A/s | New | +1,214,126 | +$3.76M | 0.7% |
| Carisma Therapeutics Inc | Exited | −1,473,240 | −$47.9K | — |
quarter ended March 31, 2026 · filed May 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Eikon Therapeutics Inc | New | +1,666,666 | +$17.6M | 5.0% |
| Aktis Oncology Inc | New | +952,844 | +$17M | 4.9% |
| Xilio Therapeutics Inc | Exited | −1,483,758 | −$950K | — |
| Xilio Therapeutics Inc | New | +105,982 | +$891K | 0.3% |
| Tuhura Biosciences | Added | +5,495 | +$9.84K | — |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sutro Biopharma Inc | Trimmed | −2,451,158 | −$28.4M | 1.1% |
| Lava Therapeutics Nv | Exited | −1,149,345 | −$1.79M | — |
quarter ended September 30, 2025 · filed November 12, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tuhura Biosciences | New | +13,950 | +$31.1K | — |
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Absci Corporation | Exited | −998,163 | −$2.62M | — |
| EB Evaxion Biotech A/s | Added | +671,847 | +$1.24M | 1.4% |
Loading...
